{"filings":[{"id":2520836,"accession_number":"0001140361-26-034698","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-08-27T20:15:47+00:00","items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.","Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.","Total consideration ~$2.2B funded from argenx cash; covers options, RSUs, warrants.","All prior directors/officers replaced; new board includes Arjen Lemmen, Karl Gubitz, Malini Moorthy.","Company requested Nasdaq delisting and will file Form 15 to suspend SEC reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-27","daily_digest_url":"/daily/2026-08-27","daily_digest_rank":7},{"id":1867519,"accession_number":"0001193125-26-316766","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-07-27T10:06:03+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"argenx to acquire Forte Biosciences for $77/share (~$2.2B); adds anti-CD122 antibody FB102","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["argenx to acquire Forte Biosciences for $77/share in cash, total equity value ~$2.2B.","Offer price represents ~86% premium to Forte's VWAP since positive Phase 1b vitiligo data on July 9, 2026.","Acquisition adds first-in-class anti-CD122 antibody FB102 with clinical proof-of-concept in vitiligo and celiac disease.","Forte board unanimously recommends; tender offer requires majority of shares tendered and HSR clearance.","Supporting stockholders (directors/officers) owning ~1% of shares have agreed to tender."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1535837,"accession_number":"0001193125-26-299177","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-07-09T12:05:21+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences reports positive Phase 1b vitiligo results for FB102; statistically significant FVASI improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p=0.020) vs placebo 7.9% improvement.","Statistically significant improvement observed by day 64 (p=0.023) and continued through week 24 after 12-week treatment.","In subjects with baseline FVASI ≥0.75, FB102 showed 43.2% mean improvement (p=0.006); 58.8% achieved FVASI50, 23.5% FVASI75.","84% (27/32) of FB102-treated subjects improved from baseline to week 24; 0% worsened vs 27% of placebo worsened.","FB102 demonstrated strong safety profile with only mild to moderate AEs, comparing favorably to placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":805637,"accession_number":"0001193125-26-253436","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-06-02T20:01:14+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.","Class III directors elected: Steven Kornfeld, Scott Brun, Paul A. Wagner (vote results provided).","Advisory vote on named executive officer compensation for FY2025 passed (12.1M for, 3.8M against, 1.5M broker non-votes).","KPMG ratified as independent auditor for FY2026 (17.7M for, 3K against, 40K abstentions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443956,"accession_number":"0001193125-26-224214","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-05-14T20:42:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.","FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.","Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.","R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.","In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92742,"accession_number":"0001193125-26-148796","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.","Underwriters have 30-day option to buy up to 856,490 additional shares.","Offering expected to close April 10, 2026; net proceeds ~$141M.","Proceeds to fund working capital and clinical development of autoimmune product candidate.","Strategic investment from argenx BV noted; Guggenheim and Barclays are joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92741,"accession_number":"0001193125-26-135767","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.","Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.","Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.","Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120097,"accession_number":"0001193125-25-281807","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.","R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.","Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.","FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.","Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136675,"accession_number":"0001193125-25-180771","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.","Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.","Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.","Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153887,"accession_number":"0001193125-25-147017","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences prices $75M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,630,450 shares at $12.00/share and 619,606 pre-funded warrants at $11.999/warrant.","Gross proceeds expected ~$75M; net ~$70M (or ~$80.5M if underwriters' option exercised).","Proceeds for working capital, general corporate purposes, funding clinical/preclinical development.","Offering expected to close June 26, 2025, subject to customary closing conditions.","Underwriters granted 30-day option to purchase up to 937,508 additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153886,"accession_number":"0001193125-25-144174","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).","CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).","Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).","No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.","Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153885,"accession_number":"0001193125-25-131525","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Forte Biosciences annual meeting elects directors; auditor ratification approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Richard Vincent, Shiv Kapoor, and David Gryska as Class II directors until 2028.","David Gryska received 2,786,414 votes for and 1,313,237 withheld (32% withheld).","Ratified KPMG LLP as independent auditor for FY2025 with 5,285,363 votes for, 2,987 against.","5,288,388 shares represented out of 6,583,382 outstanding (80.3% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153884,"accession_number":"0001193125-25-120772","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.","Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.","FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.","R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.","Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153883,"accession_number":"0001193125-25-085762","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Forte Biosciences sets annual meeting for May 29, 2025; proposals due April 28","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for May 29, 2025, more than 30 days before the 2024 anniversary.","Stockholder proposals for proxy inclusion must be received by April 28, 2025.","Director nominations and other proposals (non-14a-8) due no later than April 28, 2025.","Universal proxy rule compliance notices for soliciting support of non-company nominees due April 28, 2025.","Prior deadlines for stockholder submissions are no longer applicable due to the revised meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153882,"accession_number":"0001193125-25-073403","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.","Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.","FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.","First FB102 vitiligo patient dosing expected shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172550,"accession_number":"0001193125-25-012236","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Forte Biosciences stockholders approve amended equity plan adding 3.34M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved A&R 2021 Equity Incentive Plan on Jan 24, 2025; 2.19M for, 0.47M against, 1.38M abstain.","Plan adds 3,340,000 shares to reserve plus up to 44,093 from forfeited prior plan awards.","Plan authorizes grants of options, SARs, restricted stock, RSUs, performance awards to employees, directors, consultants.","Plan prohibits Exchange Programs (no repricing or cancellation of underwater awards without shareholder approval)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189542,"accession_number":"0001193125-24-269949","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Forte Biosciences hosts R&D Day focusing on FB102 autoimmune updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["R&D Day held December 3, 2024 highlighting FB102 development in autoimmune indications.","Slide deck (Ex-99.1) and updated corporate presentation (Ex-99.2) furnished with the filing.","No specific clinical data or financial guidance disclosed in the 8-K or exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189541,"accession_number":"0001193125-24-262543","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.","Private placement expected to close November 21, 2024; net proceeds for working capital and general corporate purposes.","FB102 healthy volunteer study completed; celiac disease trial topline readout projected Q2 2025.","Additional indications expected over next 12 months; R&D Day on December 3, 2024.","CEO Paul Wagner says financing is transformative and well capitalized for continued advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189540,"accession_number":"0001193125-24-258537","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosing begun in celiac disease trial; topline data expected Q2 2025.","Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.","Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).","Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206041,"accession_number":"0001193125-24-222962","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.","Richard Vincent and Shiv Kapoor appointed as Class II directors; to stand for election at 2025 annual meeting.","Steven Kornfeld and Scott Brun reclassified from Class II to Class III to maintain class sizes.","Camac Fund lawsuit settled; company to pay $1.5M for attorneys' fees; case dismissed with prejudice as to Camac; Standstill Agreement stands.","Board established Strategic Committee of independent directors; Rights Agreement (poison pill) expired July 12, 2024, not renewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206040,"accession_number":"0001193125-24-211066","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Forte Biosciences implements 1-for-25 reverse stock split effective August 28, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio effective 8:00 a.m. ET on August 28, 2024.","No fractional shares issued; cash paid for fractional shares based on Aug 27 closing price.","CUSIP changed to 34962G 208; trading symbol FBRX unchanged on Nasdaq.","Proportionate adjustments made to equity incentive plans and outstanding awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206039,"accession_number":"0001193125-24-205350","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.","Stockholders approved amendment to effect reverse split (26.7M for, 2.1M against).","Amended 2021 Equity Incentive Plan approved (17.3M for, 6.9M against); adds up to 8.5M new shares plus up to 1.1M from prior plans.","Class I directors elected: Barbara K. Finck, M.D. (18.8M for), Donald A. Williams (15.4M for), Stephen K. Doberstein (15.1M for).","KPMG LLP ratified as independent auditor for FY2024 with 28.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206038,"accession_number":"0001193125-24-200673","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).","Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).","FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.","Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.","G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223064,"accession_number":"0001193125-24-161592","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.","Strategic alternatives committee formed including Camac nominees; rights plan expires July 12, 2024, not renewed, no new plan for 3 years.","Camac enters standstill/voting agreement through 2028; company pays $364k for Camac's 2023 proxy contest out-of-pocket expenses.","Settlement resolves claims that July 2023 private placement (~$25M) was intended to entrench board and block Camac director nominees.","The standstill prohibits Camac from acquiring additional shares, launching proxy contests, or seeking board representation until 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223063,"accession_number":"0001193125-24-137210","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).","R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).","Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.","FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.","Company updated corporate presentation (Exhibit 99.2) for investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242554,"accession_number":"0001193125-24-070158","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.","R&D expenses rose to $21.9M from $5.6M, primarily due to FB-102 manufacturing and clinical costs.","Cash and equivalents of $37.1M at year-end 2023, down from $41.1M at end of 2022.","FB-102 Phase 1 SAD portion completed; multiple ascending dose (MAD) cohorts now dosing.","Shares outstanding of 36.3M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242553,"accession_number":"0001193125-24-038496","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K/A","filed_at":"2024-02-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Forte Biosciences board sets advisory vote on executive pay every three years","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders at Sept. 19, 2023 annual meeting cast highest votes for annual say-on-pay, second highest for triennial.","Board decided to hold advisory vote on executive compensation every three years, citing longer-term focus.","Next vote on frequency of say-on-pay will occur no later than 2029.","41.3% of votes favored triennial frequency; board considered equity vesting and strategic long-term decisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259947,"accession_number":"0001193125-23-291670","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"Forte Biosciences appoints KPMG as new independent auditor for FY2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved KPMG LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2023.","Prior auditor Mayer Hoffman McCann P.C. (MHM) declined reappointment on July 31, 2023.","No disagreements or reportable events occurred during previous fiscal years or interim period through Dec 4, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277220,"accession_number":"0001193125-23-242481","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K/A","filed_at":"2023-09-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Forte Biosciences reports final 2023 annual meeting results; say-on-pay fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two Class III directors elected: Eichenfield (16.4M for) and Wagner (16.8M for); McIntyre and Hacke not elected.","Advisory vote on executive compensation failed: 9.9M for, 11.8M against, 5.8M abstain.","Stockholders favored annual say-on-pay frequency (13.96M votes); Board to decide.","Ratification of Mayer Hoffman McCann as auditor passed (17.3M for, 3.8M against).","Amended equity plan approved; two shareholder proposals (bylaws, preferred stock rights) voted down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277224,"accession_number":"0001193125-23-238588","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Forte Biosciences annual meeting: two directors elected, say-on-pay fails, equity plan approved","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Preliminary vote shows Eichenfield (16.4M for) and Wagner (16.8M for) elected; McIntyre and Hacke not elected.","Advisory vote on executive compensation failed: 9.9M for vs 11.8M against; abstentions 5.8M.","Amended 2021 Equity Incentive Plan approved: 16.8M for, 8.5M against, 2.1M abstentions.","Shareholder proposals to amend bylaws and remove preferred stock rights both defeated.","Ratification of auditor Mayer Hoffman McCann passed with 17.3M for; results subject to final certification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277223,"accession_number":"0001193125-23-238557","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Forte Biosciences receives Nasdaq bid price deficiency notice; 180 days to comply","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Sept 14, 2023 for bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days, until March 12, 2024, to regain compliance by closing bid price >= $1.00 for 10 consecutive business days.","No immediate impact on listing or trading; may be eligible for additional 180-day compliance period if needed.","Intends to monitor bid price and consider options, including potential reverse stock split to cure deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277222,"accession_number":"0001193125-23-203902","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Auditor Mayer Hoffman McCann declines reappointment; FY2022 tax-provision controls deemed ineffective","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MHM will not stand for re-appointment for FY2024; will cease by new auditor appointment, filing of 2023 10-K, or April 1, 2024.","No disagreements between company and MHM on accounting principles or audit scope for FY2021 and FY2022.","Reportable event: management concluded ineffective controls over completeness and accuracy of annual tax provision in FY2022 10-K.","Audit committee will initiate process to select a new independent registered public accounting firm.","MHM’s audit reports for FY2021 and FY2022 were unqualified, with no adverse opinion or disclaimer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277221,"accession_number":"0001193125-23-200540","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["1.01","3.02","3.03","7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences raises $25M in private placement; announces promising FB-102 data in GvHD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$25M gross from private placement with top-tier institutional investors; execs and board purchased $1.16M.","FB-102 (anti-CD122) showed 90% survival in acute GvHD model vs 0% vehicle, superior to ruxolitinib (60% single agent).","Combination of FB-102 with ruxolitinib yielded 90% survival vs 30% for ruxolitinib alone in preclinical model.","Forte plans to advance FB-102 into clinic in 2024; preclinical PoC data supports potential in vitiligo, celiac, alopecia, T1D, and transplant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295117,"accession_number":"0001193125-23-175223","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01","3.03","5.08","8.01","9.01"],"status":"ready","headline":"Forte Biosciences extends rights agreement expiration to July 2024; sets 2023 annual meeting for September 19","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment No. 1 extends Rights Agreement expiration to 5:00 p.m. ET on July 12, 2024, unless earlier redeemed or exchanged.","2023 Annual Meeting of Stockholders scheduled for September 19, 2023.","Stockholder proposals for proxy inclusion or director nominations must be received by July 6, 2023.","All other terms of the Rights Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315693,"accession_number":"0001193125-23-088024","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.9M ($0.80/sh) vs $21.7M ($1.55/sh) in FY 2021; cash and equivalents $41.1M at year-end.","R&D expenses decreased to $5.6M from $13.9M due to termination of FB-401; G&A rose to $8.3M.","Lead candidate FB-102 for autoimmune diseases expected to enter clinic in late 2023 or early 2024.","Board appointed David Gryska (former CFO of Incyte and Celgene) in January 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315692,"accession_number":"0001193125-23-030275","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Forte Biosciences amends bylaws to update stockholder meeting procedures","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bylaws revised to require stockholder nominating directors to deliver evidence of Rule 14a-19 compliance at least 5 business days before meeting.","Changes conform to recent amendments to the Delaware General Corporation Law.","Amendments also include ministerial and clarifying revisions to align with current Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315691,"accession_number":"0001193125-23-007190","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2023-01-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences appoints David Gryska to board; Patricia Walker resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Gryska appointed as Class II director effective January 10, 2023; serves on Audit Committee.","Gryska is former CFO/Exec VP of Incyte and Celgene; receives 50,000 stock option vesting over 3 years.","Patricia Walker resigned from board and all committees effective January 6, 2023; no disagreement cited.","Gryska will receive $40,000/year as director plus $8,000/year for Audit Committee service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334028,"accession_number":"0001193125-22-284535","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences Q3 net loss narrows to $0.18/sh; cash $44M; appoints Scott Brun to board","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2022 net loss $3.4M ($0.18/share) vs $7.8M ($0.54) in Q3 2021; R&D expenses fell to $1.4M.","Cash and equivalents $44.0M at Sept 30, 2022; 21.0M shares outstanding; no revenue.","Lead candidate FB-102 on track for clinic late 2023/early 2024; addressable market >$6B.","Appointed Scott Brun, M.D. to Board (effective Nov 10); ex-Head of AbbVie Ventures and Product Development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351454,"accession_number":"0001193125-22-221213","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.","Cash and equivalents $38.5M as of June 30, 2022; raised $7.0M via ATM in July/August.","R&D spend down to $1.0M from $3.5M YoY as FB-401 wound down; focus shifting to autoimmune pipeline.","Lead candidate FB-102 expected to enter clinic late 2023 or early 2024 for GvHD, vitiligo, alopecia areata.","Appointed Hubert Chen as CSO and President; added Stephen Doberstein to board of directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351453,"accession_number":"0001193125-22-220060","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Forte Biosciences files prospectus supplement for additional $2.7M ATM offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed new prospectus supplement for sale of up to $2.7M of common stock via existing ATM agreement with Ladenburg Thalmann.","Aggregate offering under the ATM agreement remains capped at $25M; previously $7M was registered.","Proceeds to be used for general corporate purposes, including funding existing and potential new clinical programs.","Shares issued under previously effective S-3 registration statement filed May 28, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351452,"accession_number":"0001193125-22-191783","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Forte Biosciences adopts poison pill rights plan with 10% trigger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declares dividend of one Right per share of common stock; record date July 21, 2022.","Rights exercisable at $16 per one thousandth of Series A Participating Preferred share.","Rights become exercisable if a person acquires 10% (20% for certain institutional holders) of common stock.","Rights expire on July 12, 2023, redeemable at $0.001 per Right at board's option.","Certificate of Designation for Series A Preferred filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368816,"accession_number":"0001193125-22-168911","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences appoints Dr. Hubert Chen as President and CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Chen appointed President and Chief Scientific Officer effective June 7, 2022; Paul Wagner remains CEO.","Annual base salary of $450,000, target annual bonus of 40% of base salary, and option for 250,000 shares.","Dr. Chen previously served as CMO of Metacrine and CSO/CMO of Pfenex, leading PF708 NDA and MAA approvals.","Options vest 25% after one year, remaining monthly over 36 months; grant under 2020 Inducement Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368815,"accession_number":"0001193125-22-166208","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Forte Biosciences shareholders elect two Class II directors, ratify auditor, approve equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Steven Kornfeld elected Class II director with 3,366,874 votes for; Patricia Walker with 3,335,739 for, 1,612,841 withheld; 3,373,670 broker non-votes.","Ratification of Mayer Hoffman McCann as independent auditor for FY2022: 8,107,698 for, 157,062 against, 57,490 abstentions.","Increase to 2021 Equity Incentive Plan approved: 2,826,803 for, 2,106,190 against, 15,587 abstentions, 3,373,670 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368814,"accession_number":"0001193125-22-151007","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-05-16T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences Q1 net loss $2.6M; cash $40M to fund operations for 24 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.17 per share) vs $4.8M ($0.36) in Q1 2021; R&D spend down to $0.7M on wind-down of FB-401.","Cash and cash equivalents $40.0M; cash burn $2.0M in Q1; sufficient for at least 24 months.","Lead asset FB-102 for autoimmune diseases expected to enter clinic in H2 2023.","Appointed Stephen Doberstein, Ph.D. and Barbara Finck, M.D. to board of directors.","14.8M shares outstanding as of March 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368813,"accession_number":"0001193125-22-092360","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-04-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Forte Biosciences enters ATM equity sales agreement for up to $25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Ladenburg Thalmann allows sale of up to $25M common stock; initial prospectus supplement covers $7M.","Commission of 3.0% of gross proceeds payable to Ladenburg for at-the-market sales.","Net proceeds to be used for general corporate purposes and funding of clinical programs.","Company not obligated to sell any shares; sales will be at prevailing market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388055,"accession_number":"0001193125-22-079036","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-03-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Forte Biosciences appoints Barbara K. Finck, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective March 16, 2022; Dr. Finck will serve as a Class I director until 2024 annual meeting.","Annual cash retainer of $40,000, paid quarterly in arrears on a pro-rata basis.","Granted option for 50,000 shares of common stock vesting monthly over three years.","Dr. Finck currently acting Chief Medical Officer at Coherus BioSciences; prior CMO at NKT Therapeutics and Osprey Pharmaceuticals.","No arrangement with any other person for election; no family relationships with directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388054,"accession_number":"0001193125-22-025772","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Forte Biosciences terminates patent license agreement with NIAID, effective April 2, 2022","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Terminated Patent License Agreement with National Institute of Allergy and Infectious Diseases (NIAID).","Termination effective April 2, 2022.","Company will have no future payment obligations under the Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425013,"accession_number":"0001193125-21-264493","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Forte Biosciences FB-401 Phase 2 atopic dermatitis trial misses primary endpoint EASI-50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint EASI-50: 58% active vs 60% placebo (p=0.7567), not statistically significant.","Secondary endpoint EASI-90: 27.6% active vs 20.5% placebo (p=0.3075); IGA success: 38.2% vs 29.5% (p=0.2599).","Company will not continue development of FB-401; plans to provide future update on company direction.","Cash and cash equivalents of $50.8 million as of June 30, 2021.","Previously scheduled September 7 conference call canceled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}